Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$81.16 USD

81.16
7,966,400

+0.27 (0.33%)

Updated Sep 10, 2024 04:00 PM ET

After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Relay Stock Soars on Upbeat Data From Breast Cancer Study

by Zacks Equity Research

RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.

GSK's Respiratory Drug Nucala Meets Goal in COPD Study

by Zacks Equity Research

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

by Zacks Equity Research

MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.

QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases

by Zacks Equity Research

QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.

Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?

by Zacks Equity Research

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights Visa, AstraZeneca, Disney, FitLife Brands and Utah Medical

by Zacks Equity Research

Visa, AstraZeneca, Disney, FitLife Brands and Utah Medical are included in this Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Linde, AstraZeneca & Walt Disney

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and The Walt Disney Company (DIS), as well as two micro-cap stocks FitLife Brands, Inc. (FTLF) and Utah Medical Products, Inc. (UTMD).

J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC

by Zacks Equity Research

The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.

Roche Obtains Approval For its Rare Blood Disorder Drug in the EU

by Zacks Equity Research

RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.

Insmed Stock Surges 168% in the Past Six Months: Here's Why

by Zacks Equity Research

Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

by Zacks Equity Research

Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.

Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

by Zacks Equity Research

Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

by Zacks Equity Research

The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.

Kinjel Shah headshot

How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?

by Kinjel Shah

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

by Zacks Equity Research

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.

Sundeep Ganoria headshot

Medicare Releases Negotiated Prices on 10 Expensive Drugs

by Sundeep Ganoria

Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.

Kinjel Shah headshot

Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal

by Kinjel Shah

Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.

Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?

by Zacks Equity Research

Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.

Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.

Sheraz Mian headshot

Top Analyst Reports for AstraZeneca, TotalEnergies & ConocoPhillips

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), TotalEnergies SE (TTE) and ConocoPhillips (COP).

Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.

The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi

by Zacks Equity Research

AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.

Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises

by Zacks Equity Research

Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024.

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View

by Zacks Equity Research

Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.